Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial

Lihui Zhang(Hebei Medical University), Shuang Yan(Cancer Institute (WIA)), Sheng'ai Shen(Yanbian University Hospital), Zhixia Yang(Mudanjiang Medical University), Luling Dong(Kailuan General Hospital), Qiang Lü(First Hospital of Qinhuangdao), Fang Hou, Guangwei Li(Hebei Medical University), Lin Qi(Hebei Medical University), Yufeng Li(Jilin University of Finance and Economics), Ningling Sun(Peking University), Yanjie Liu(Harbin Medical University), Jianling Du(Dalian Medical University), Lian Xu(Fuzhou University), Qiuyun Li(Harbin Medical University), Weidong Ren(Hebei North University), Wenli Cheng(Beijing Anzhen Hospital), Dong‐Hong Wu(The First Hospital of Kunming), Qiuhong Gong(Chinese Academy of Medical Sciences & Peking Union Medical College)
The Lancet Diabetes & Endocrinology
July 3, 2023
Cited by 83


Related Papers